Table 2. Monte-Carlo simulation of 10,000 patients (mean±SD); Rate of hepatocellular carcinoma (HCC).

		Rate of HCC
METAVIR	Age	No Treatment	Treatment
F2	50	37.1% ± 16.5%	8.8% ± 0.8%
	70	21.0% ± 4.6%	4.5% ± 0.3%
F3	50	42.8% ± 24.1%	8.7% ± 0.8%
	70	30.3% ± 10.2%	5.7% ± 0.4%
F4	50	48.6% ± 38.5%	39.9% ± 19.9%
	70	42.2% ± 23.2%	32.4% ± 11.9%